Cargando…

Physiologically Based Pharmacokinetic Modeling Is Essential in (90)Y-Labeled Anti-CD66 Radioimmunotherapy

INTRODUCTION: Radioimmunotherapy (RIT) with (90)Y-labeled anti-CD66 antibody is used to selectively irradiate the red marrow (RM) before blood stem cell transplantation of acute leukemia patients. To calculate the activity to administer, time-integrated activity coefficients are required. These are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kletting, Peter, Maaß, Christian, Reske, Sven, Beer, Ambros J., Glatting, Gerhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444288/ https://www.ncbi.nlm.nih.gov/pubmed/26010360 http://dx.doi.org/10.1371/journal.pone.0127934

Ejemplares similares

Optimization of Radiolabeling of a [(90)Y]Y-Anti-CD66-Antibody for Radioimmunotherapy before Allogeneic Hematopoietic Cell Transplantation
por: Winter, Gordon, et al.
Publicado: (2023)

A Physiologically Based Pharmacokinetic Model for In Vivo Alpha Particle Generators Targeting Neuroendocrine Tumors in Mice
por: Zaid, Nouran R. R., et al.
Publicado: (2021)

Influence of sampling schedules on [(177)Lu]Lu-PSMA dosimetry
por: Rinscheid, Andreas, et al.
Publicado: (2020)

Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for (177)Lu-Labeled PSMA-Targeting Peptides
por: Kletting, Peter, et al.
Publicado: (2016)

The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model
por: Begum, Nusrat J., et al.
Publicado: (2019)

A population-based method to determine the time-integrated activity in molecular radiotherapy
por: Hardiansyah, Deni, et al.
Publicado: (2021)

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
por: Meyer, Catherine, et al.
Publicado: (2022)

Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling schedule
por: Maaß, Christian, et al.
Publicado: (2016)

Therapeutic efficacy evaluation of radioimmunotherapy with (90)Y‐labeled anti‐podoplanin antibody NZ‐12 for mesothelioma
por: Sudo, Hitomi, et al.
Publicado: (2019)

Development of DOTA-Rituximab to be Labeled with (90)Y for Radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
por: Johari doha, Fariba, et al.
Publicado: (2017)

Yttrium-90-Labeled Anti-Glypican 3 Radioimmunotherapy Halts Tumor Growth in an Orthotopic Xenograft Model of Hepatocellular Carcinoma
por: Ludwig, Andrew D., et al.
Publicado: (2019)

Single-time-point dosimetry using model selection and nonlinear mixed-effects modelling: a proof of concept
por: Hardiansyah, Deni, et al.
Publicado: (2023)

Single-time-point estimation of absorbed doses in PRRT using a non-linear mixed-effects model
por: Hardiansyah, Deni, et al.
Publicado: (2022)

Anti-CD45 Radioimmunotherapy with (90)Y but Not (177)Lu Is Effective Treatment in a Syngeneic Murine Leukemia Model
por: Orozco, Johnnie J., et al.
Publicado: (2014)

Comparative Efficacy of (177)Lu and (90)Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models
por: Frost, Sofia H. L., et al.
Publicado: (2015)

Evaluation of Efficacy of Radioimmunotherapy with (90)Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models
por: Sugyo, Aya, et al.
Publicado: (2015)

Radioimmunotherapy of pancreatic cancer xenografts in nude mice using (90)Y-labeled anti-α(6)β(4) integrin antibody
por: Aung, Winn, et al.
Publicado: (2016)

Radioimmunotherapy with an (211)At‐labeled anti–tissue factor antibody protected by sodium ascorbate
por: Takashima, Hiroki, et al.
Publicado: (2021)

Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma
por: Westrøm, Sara, et al.
Publicado: (2016)

Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies
por: Dillman, R. O.
Publicado: (2006)

Therapeutic Efficacy of C-Kit-Targeted Radioimmunotherapy Using 90Y-Labeled Anti-C-Kit Antibodies in a Mouse Model of Small Cell Lung Cancer
por: Yoshida, Chisato, et al.
Publicado: (2013)

A (90)Y-labelled anti-ROBO1 monoclonal antibody exhibits antitumour activity against hepatocellular carcinoma xenografts during ROBO1-targeted radioimmunotherapy
por: Fujiwara, Kentaro, et al.
Publicado: (2014)

Radioimmunotherapy for Liver Micrometastases in Mice: Pharmacokinetics, Dose Estimation, and Long‐term Effect
por: Saga, Tsuneo, et al.
Publicado: (1999)

Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: A pilot study
por: Grana, C, et al.
Publicado: (2002)

Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target
por: Sabanathan, Dhanusha, et al.
Publicado: (2021)

Immunostimulatory effects of radioimmunotherapy
por: Constanzo, Julie, et al.
Publicado: (2022)

Dynamic Metabolic Changes during the First 3 Months after (90)Y-Ibritumomab Tiuxetan Radioimmunotherapy
por: Takahashi, Miwako, et al.
Publicado: (2014)

Radioimmunotherapy of human hepatocellular carcinoma xenografts with 131I-labelled antiferritin antibody.
por: Saiful Alam, A. F.
Publicado: (1991)

Radioimmunotherapy study of (131)I-labeled Atezolizumab in preclinical models of colorectal cancer
por: Zhang, Linhan, et al.
Publicado: (2022)

Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep
por: Baur, Benjamin, et al.
Publicado: (2014)

Development Of [(211)At]Astatine-Based Anti-CD123 Radioimmunotherapy For Acute Leukemias and Other CD123+ Malignancies
por: Laszlo, George S., et al.
Publicado: (2022)

Efficacy Evaluation of Combination Treatment Using Gemcitabine and Radioimmunotherapy with (90)Y-Labeled Fully Human Anti-CD147 Monoclonal Antibody 059-053 in a BxPC-3 Xenograft Mouse Model of Refractory Pancreatic Cancer
por: Sugyo, Aya, et al.
Publicado: (2018)

Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma
por: Herrera, Alex F., et al.
Publicado: (2021)

Quantitative analysis of regional distribution of tau pathology with (11)C-PBB3-PET in a clinical setting
por: Yousefzadeh-Nowshahr, Elham, et al.
Publicado: (2022)

Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry
por: Hohloch, Karin, et al.
Publicado: (2020)

Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients
por: Bodet-Milin, Caroline, et al.
Publicado: (2015)

Radioimmunotherapy of transplanted small cell lung cancer with 131I-labelled monoclonal antibody.
por: Yoneda, S., et al.
Publicado: (1988)

Preclinical PET and MR Evaluation of (89)Zr- and (68)Ga-Labeled Nanodiamonds in Mice over Different Time Scales
por: Winter, Gordon, et al.
Publicado: (2022)

Pretargeted Molecular Imaging and Radioimmunotherapy
por: Goldenberg, David M., et al.
Publicado: (2012)

Radioimmunotherapy: a brief overview
por: Ng, DCE
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_fqc2kf0aqbotfsih7l53et9moh